Werewolf Therapeutics, Inc. (HOWL)

Market Cap	72.03M
Revenue (ttm)	24.80M
Net Income (ttm)	-40.95M
Shares Out	35.66M
EPS (ttm)	-1.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,760
Open	2.27
Previous Close	2.21
Day's Range	2.02 - 2.27
52-Week Range	1.39 - 5.53
Beta	0.16
Analysts	Strong Buy
Price Target	10.58 (+423.76%)
Earnings Date	Nov 9, 2023

About HOWL

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or met...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2021
• Employees: 48
• Stock Exchange: NASDAQ
• Ticker Symbol: HOWL

Analyst Forecast

According to 4 analysts, the average rating for HOWL stock is "Strong Buy." The 12-month stock price forecast is $10.58, which is an increase of 423.76% from the latest price.

Price Target

$10.58

(423.76% upside)

Analyst Consensus: Strong Buy